MA38410A1 - Composés d'azétidinyloxyphénylpyrrolidine - Google Patents
Composés d'azétidinyloxyphénylpyrrolidineInfo
- Publication number
- MA38410A1 MA38410A1 MA38410A MA38410A MA38410A1 MA 38410 A1 MA38410 A1 MA 38410A1 MA 38410 A MA38410 A MA 38410A MA 38410 A MA38410 A MA 38410A MA 38410 A1 MA38410 A1 MA 38410A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- formula
- relates
- azetidinyloxyphenylpyrrolidine
- azetidinyloxyphenylpyrrolidine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne certains composés d'azétidinyloxyphénylpyrrolidine, en particulier des composés représentés par la formule i, dans laquelle r désigne hydrogène ou méthyle, ainsi que des compositions pharmaceutiques associées. L'invention concerne également des procédés d'utilisation d'un composé représenté par la formule i pour le traitement de la vessie hyperactive.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778546P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/021474 WO2014159012A1 (fr) | 2013-03-13 | 2014-03-07 | Composés d'azétidinyloxyphénylpyrrolidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38410A1 true MA38410A1 (fr) | 2016-02-29 |
| MA38410B1 MA38410B1 (fr) | 2016-09-30 |
Family
ID=50382705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38410A MA38410B1 (fr) | 2013-03-13 | 2014-03-07 | Composés d'azétidinyloxyphénylpyrrolidine |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US9034864B2 (fr) |
| EP (2) | EP2970222B1 (fr) |
| JP (2) | JP6017708B2 (fr) |
| KR (2) | KR101745304B1 (fr) |
| CN (2) | CN109336865A (fr) |
| AP (1) | AP3850A (fr) |
| AR (1) | AR095015A1 (fr) |
| AU (1) | AU2014241444B2 (fr) |
| BR (1) | BR112015020222B1 (fr) |
| CA (1) | CA2899806C (fr) |
| CL (1) | CL2015002113A1 (fr) |
| CR (1) | CR20150417A (fr) |
| CY (1) | CY1120142T1 (fr) |
| DK (1) | DK2970222T3 (fr) |
| DO (1) | DOP2015000176A (fr) |
| EA (1) | EA026631B1 (fr) |
| ES (1) | ES2616470T3 (fr) |
| HR (1) | HRP20170080T1 (fr) |
| HU (1) | HUE032235T2 (fr) |
| IL (1) | IL240904B (fr) |
| JO (1) | JO3264B1 (fr) |
| LT (1) | LT2970222T (fr) |
| MA (1) | MA38410B1 (fr) |
| ME (1) | ME02592B (fr) |
| MX (1) | MX373636B (fr) |
| MY (1) | MY180006A (fr) |
| NZ (1) | NZ710481A (fr) |
| PE (1) | PE20151669A1 (fr) |
| PH (1) | PH12015502032A1 (fr) |
| PL (1) | PL2970222T3 (fr) |
| PT (1) | PT2970222T (fr) |
| RS (1) | RS55594B1 (fr) |
| SG (2) | SG11201507501YA (fr) |
| SI (1) | SI2970222T1 (fr) |
| TN (1) | TN2015000384A1 (fr) |
| TW (1) | TWI617553B (fr) |
| UA (1) | UA115583C2 (fr) |
| WO (1) | WO2014159012A1 (fr) |
| ZA (1) | ZA201505417B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI617553B (zh) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
| WO2016033776A1 (fr) * | 2014-09-04 | 2016-03-10 | Eli Lilly And Company | (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl)-3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin |
| AR101696A1 (es) * | 2014-09-12 | 2017-01-04 | Lilly Co Eli | Compuestos de azetidiniloxifenilpirrolidina |
| CN111333625B (zh) * | 2018-12-18 | 2022-10-18 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类化合物及其用途 |
| CN111333637B (zh) * | 2018-12-18 | 2022-07-29 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类衍生物及其制备方法 |
| KR20210093320A (ko) * | 2018-12-18 | 2021-07-27 | 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 | 페닐피롤리딘계 화합물 및 그의 용도 |
| WO2021036953A1 (fr) * | 2019-08-23 | 2021-03-04 | 湖北生物医药产业技术研究院有限公司 | Composé phénylpyrrolidine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| JPH07300455A (ja) * | 1994-03-08 | 1995-11-14 | Mitsubishi Chem Corp | ３−フェニルピロリジン誘導体 |
| DE19601938A1 (de) * | 1996-01-12 | 1997-07-17 | Schering Ag | Neue Phosphodiesteraseinhibitoren |
| US6376489B1 (en) * | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6258833B1 (en) | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| OA12542A (en) * | 2001-01-31 | 2006-06-05 | Pfizer Prod Inc | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes. |
| CA2623657A1 (fr) | 2005-09-29 | 2007-04-12 | Bayer Healthcare Ag | Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires |
| TW201206440A (en) | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| TWI617553B (zh) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
-
2014
- 2014-03-04 TW TW103107294A patent/TWI617553B/zh active
- 2014-03-04 JO JOP/2014/0068A patent/JO3264B1/ar active
- 2014-03-05 AR ARP140100712A patent/AR095015A1/es active IP Right Grant
- 2014-03-07 AU AU2014241444A patent/AU2014241444B2/en active Active
- 2014-03-07 PT PT147129688T patent/PT2970222T/pt unknown
- 2014-03-07 US US14/200,376 patent/US9034864B2/en active Active
- 2014-03-07 DK DK14712968.8T patent/DK2970222T3/en active
- 2014-03-07 MY MYPI2015703060A patent/MY180006A/en unknown
- 2014-03-07 EP EP14712968.8A patent/EP2970222B1/fr active Active
- 2014-03-07 HU HUE14712968A patent/HUE032235T2/en unknown
- 2014-03-07 CN CN201811189530.XA patent/CN109336865A/zh active Pending
- 2014-03-07 UA UAA201508671A patent/UA115583C2/uk unknown
- 2014-03-07 PE PE2015001904A patent/PE20151669A1/es active IP Right Grant
- 2014-03-07 WO PCT/US2014/021474 patent/WO2014159012A1/fr not_active Ceased
- 2014-03-07 PL PL14712968T patent/PL2970222T3/pl unknown
- 2014-03-07 RS RS20170035A patent/RS55594B1/sr unknown
- 2014-03-07 MA MA38410A patent/MA38410B1/fr unknown
- 2014-03-07 CN CN201480014091.2A patent/CN105051034B/zh active Active
- 2014-03-07 KR KR1020177002304A patent/KR101745304B1/ko active Active
- 2014-03-07 ES ES14712968.8T patent/ES2616470T3/es active Active
- 2014-03-07 EP EP16196721.1A patent/EP3168216A1/fr not_active Withdrawn
- 2014-03-07 CA CA2899806A patent/CA2899806C/fr active Active
- 2014-03-07 HR HRP20170080TT patent/HRP20170080T1/hr unknown
- 2014-03-07 SG SG11201507501YA patent/SG11201507501YA/en unknown
- 2014-03-07 BR BR112015020222-5A patent/BR112015020222B1/pt active IP Right Grant
- 2014-03-07 MX MX2015012579A patent/MX373636B/es active IP Right Grant
- 2014-03-07 SG SG10201609717YA patent/SG10201609717YA/en unknown
- 2014-03-07 SI SI201430124A patent/SI2970222T1/sl unknown
- 2014-03-07 NZ NZ710481A patent/NZ710481A/en unknown
- 2014-03-07 AP AP2015008699A patent/AP3850A/en active
- 2014-03-07 KR KR1020157024606A patent/KR101702797B1/ko active Active
- 2014-03-07 JP JP2015561688A patent/JP6017708B2/ja active Active
- 2014-03-07 EA EA201591498A patent/EA026631B1/ru not_active IP Right Cessation
- 2014-03-07 ME MEP-2017-10A patent/ME02592B/fr unknown
- 2014-03-07 LT LTEP14712968.8T patent/LT2970222T/lt unknown
-
2015
- 2015-01-13 US US14/595,262 patent/US9266859B2/en active Active
- 2015-07-24 DO DO2015000176A patent/DOP2015000176A/es unknown
- 2015-07-28 ZA ZA2015/05417A patent/ZA201505417B/en unknown
- 2015-07-29 CL CL2015002113A patent/CL2015002113A1/es unknown
- 2015-08-14 CR CR20150417A patent/CR20150417A/es unknown
- 2015-08-27 IL IL240904A patent/IL240904B/en active IP Right Grant
- 2015-09-03 TN TN2015000384A patent/TN2015000384A1/en unknown
- 2015-09-10 PH PH12015502032A patent/PH12015502032A1/en unknown
-
2016
- 2016-01-15 US US14/996,321 patent/US9604967B2/en active Active
- 2016-09-28 JP JP2016189812A patent/JP6204557B2/ja active Active
-
2017
- 2017-02-03 CY CY20171100164T patent/CY1120142T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
| EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
| MA37519B1 (fr) | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 | |
| MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA38398A1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
| MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
| MA38403A1 (fr) | Nouveaux dérivés de pyrazole modulateurs specifiques de cb2 | |
| MA38404A1 (fr) | Nouveaux dérivés de pyridine | |
| MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MX370010B (es) | Inhibidores de tirosina cinasa de bruton. | |
| MA38250B1 (fr) | Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie | |
| MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MX374759B (es) | Inhibidores de tirosina cinasa de bruton. | |
| BR112015009988A2 (pt) | melhoramentos em compostos orgânicos ou relativos | |
| MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
| MA38010B1 (fr) | Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5 | |
| MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant |